The start of a New Year is a good time to take stock of where we’ve come from and where we’re going in the fast-paced world of oncology new product development.
Upregulation doesn’t always mean a protein is a valid target, but in some cases it just might…
In this latest post, we’re revisiting T cell immunoglobulin and mucin domain-containing protein 3 – or TIM-3 in short – and taking a closer look at the evolving competitive landscape in this niche.
One company targeting it is Novartis, who have an anti-TIM–3 antibody MBG453 in development. In this post we have an expert interview with a scientist who is a pioneer in the emerging field of TIM-3 biology.
There’s also a review of some of the recent important scientific papers on TIM-3 biology, as well as commentary on data presented at ASH19 that we expect may feature in presentations at JPM20 next week, not to mention be the focus of future interim updates should the data turn out to show some promise in certain settings.
If you have an interest in targeting novel immune checkpoints and want to find out more about where the field is at with TIM-3, then this post is for you.
Curious to find out more about our latest oncology coverage and get a heads up on additional insights from our latest thought leader interview, analysis, and commentary? Subscribers can log-in or you can click to gain access to BSB Premium Content.
We are finally at the end of our AACR 2017 post meeting analysis and coverage with the final interview from Washington DC on deck. Timely wise, it’s actually quite a relevant one given the news last week on mixed results with clinical trials involving checkpoint blockade.
Just as we learned that immunotherapy agents can stop working over time, as well as the majority of patients don’t respond at all to begin with, there are concerted research efforts ongoing by both academia and industry to explore mechanisms of immune escape, resistance and modulating the tumour microenvironment.
Here we explore the intersection of targeted therapy-IO combinations, resistance and immune escape, transcription factors and other interesting new areas of development.
Also included is commentary from a leading KOL, which is NOT available on the recent Novel Targets podcast episode on overcoming immunotherapy resistance – readers should check that out first before reading this article, as this is more advanced.
Subscribers can login to read our latest expert interview